09:49 AM EST - IMV Inc. : Announced that translational data from the Phase 2 clinical study in patients with advanced, recurrent ovarian cancer will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. IMV Inc.
shares T.IMV are trading unchanged at $1.98.
